Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis
Trypanosomiasis, African
About this trial
This is an interventional treatment trial for Trypanosomiasis, African focused on measuring trypanosomiasis, gambiense, combination drug therapy, sleeping sickness, Uganda
Eligibility Criteria
Inclusion Criteria: confirmed second-stage T.b. gambiense infection : Infection diagnosed parasitologically (blood or lymph node fluid) and white blood cells > 5/mm3 in cerebrospinal fluid (CSF) or Trypanosomes detected in the CSF with any CSF cell count and resident in the district and written consent of the patient or of one of the parents/guardians for children under 15 years of age. Exclusion Criteria: Trypanosome absent from blood (or lymph node fluid) and from CSF Or women pregnant on inclusion Or previous history of HAT confirmed treated during the last 24 months Or impossibility of regular access to the treatment centre during the 2 years following the end of the treatment Or less than 10 kg of body weight Or refugee patient
Sites / Locations
- Omugo Sleeping Sickness Treatment Center